In­ven­ti­va signs over Chi­na NASH rights to Sino Bio­pharm in pos­si­ble $300M+ deal

More than two years af­ter claim­ing a Phase II win in one of the most chal­leng­ing dis­eases faced in biotech, In­ven­ti­va is hand­ing over rights in sev­er­al Asian mar­kets to a more on-site com­pa­ny.

In­ven­ti­va and Sino Bio­pharm joint­ly an­nounced the deal Wednes­day af­ter mar­ket close, where In­ven­ti­va will hand over de­vel­op­ment and com­mer­cial­iza­tion rights for NASH can­di­date lan­i­fi­bra­nor to Sino Bio­pharm sub­sidiary Chia Tai-Tian­qing Phar­ma­ceu­ti­cal Group (CT­TQ). Rights in­clude those in Chi­na, Hong Kong, Macau and Tai­wan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER